- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
**Zenith Drugs Limited Financial Summary**
Zenith Drugs Limited has reported standalone financial results for the half year ended September 30, 2024. Total revenue reached ₹68.56 crore, representing a slight decrease of 1.33% compared to ₹69.48 crore in the same period last year. This decline may be attributed to increased competition in the pharmaceutical sector impacting sales volumes.
Net profit for the period stood at ₹5.72 crore, with Earnings Per Share (EPS) recorded at ₹3.33, compared to ₹4.75 in the previous year, indicating a decrease in profitability potentially driven by rising operational costs. Operational expenses increased by 9.8%, particularly in the cost of materials consumed and employee benefits, which may put pressure on margins.
The company’s balance sheet reflects total assets of ₹143.63 crore, with shareholder equity at ₹57.38 crore. Cash flow from operating activities presented a negative figure of ₹7.93 crore, primarily due to working capital requirements that included significant increases in trade payables.
Strategically, the firm appears focused on managing costs amid industry challenges while looking for opportunities in market expansion. Market sentiment may be cautious, given the EPS decline and operational challenges.
For investors, the financial performance suggests a "hold" position as the company navigates through short-term pressures while potentially leveraging its market position for future growth opportunities.